Toho : Notice Regarding Marketing Approvals for 1 Ingredient / 2 Product of Generic Drugs for KYOSOMIRAI PHARMA(173 KB)
August 14, 2022 at 11:33 pm EDT
Share
August 15, 2022
To whom it may concern:
Company Name
TOHO HOLDINGS CO., LTD.
Corporate
Atsushi Udoh, Representative Director,
Representative
CEO
(Prime Market of Tokyo Stock Exchange
Securities Code: 8129)
Contact:
Makoto Kawamura, Corporate Officer
and General Manager, Corporate
Communications and Investor Relations
Division
(TEL: 81-3-6838-2803)
Notice Regarding Marketing Approvals for
1 Ingredient / 2 Products of Generic Drugs for KYOSOMIRAI PHARMA
TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received approvals for marketing of 1 ingredient / 2 products of generic drugs today on August 15, 2022 as below.
Products list approved for marketing
Class
Product Name
Original Brand Name
V2-receptor antagonist
Tolvaptan OD tablets
Samsca® OD tablets
7.5mg/15mg "KMP"
7.5mg/15mg
Attachments
Original Link
Original Document
Permalink
Disclaimer
Toho Holdings Co. Ltd. published this content on 15 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2022 03:32:02 UTC.
Toho Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical wholesale business. The Company operates through five business segments. The Pharmaceutical Wholesale segment purchases pharmaceuticals and medical-related products from pharmaceutical manufacturers and sells them to hospitals, clinics and dispensing pharmacies. It is also engaged in the provision of data processing system and rental of real estate. The Dispensing Pharmacy segment is engaged in the management of insurance dispensing pharmacies and dispensing pharmacies. The Pharmaceutical Manufacture and Sale segment is engaged in the manufacture and sale of generic drugs and contract manufacturing of injectable drugs. The Clinical Trial Facility Support segment is engaged in the provision of support for clinical trial facilities. The Information Equipment Sales segment is engaged in the planning and sale of information processing equipment.
TOHO HOLDINGS CO., LTD. 
